

ALOPECIA IS MORE COMMON THAN OBESITY

50% OF WOMEN AND MEN MAY BE AFFECTED BY ALOPECIA

Androgenetic alopecia is responsible for most hair loss cases—as many as 95%. Hair loss affects 1 in 2.5 people;¹ by comparison, obesity affects 1 in 8 people.² According to a CRO IQVIA 2024 report (data on file), more than 200 million patients in 15 European countries³ are affected by androgenetic alopecia, with only 85 million receiving treatment. The value of the global alopecia market could reach €16 billion by 2028, according to the CRO IQVIA report, achieving a compound annual growth rate of 10–12%.

BioResearch Pharma S.A. (BRP), a company developing novel topical dermatological therapies based on repurposing, is developing a discovery (BRP-011) with patent protection covering 15 countries in the European Union and the United Kingdom. BRP-011 has the potential to become a new standard in the treatment of alopecia and improve the quality of life for millions of patients. The company is also working on a topical drug candidate for psoriasis (BRP-007), a problem affecting about 2% of the population.

Androgenetic alopecia is a growing civilizational problem, affecting nearly 70% of men and up to 40% of women.⁴ The disease leads to a reduced quality of life for patients suffering from it and can result in depression due to low self-esteem, among other things. According to the company's market analysis, no new drug for androgenetic alopecia has been approved for more than 25 years.

According to the World Health Organization (WHO), the number of people aged 60+ will increase from about 1.0 billion in 2020 to about 1.4 billion in 2030,⁵ meaning a growing population of people facing androgenetic alopecia who will be looking for effective and readily available therapies.

“The BRP-011 product we are developing is a drug candidate for topical use in androgenetic alopecia for men and women,” explained **Łukasz Zybaczyński, CEO of BioResearch Pharma S.A.** “According to available analyses and reports, including the CRO IQVIA report developed for BRP, there are more than 200 million people with androgenetic alopecia in our patent area. The second project we are working on is BRP-007, a drug candidate for topical application in psoriasis with a novel mechanism of action. BRP's projects address unmet medical needs in

¹ <https://www.ncbi.nlm.nih.gov/books/NBK430924/>

² WHO, <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>

³ Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom

⁴ CRO IQVIA report 2024, data on file

⁵ WHO, https://www.who.int/health-topics/ageing#tab=tab_1

dermatology and, crucially, aim to improve patients' quality of life while catering to the demand of the aesthetic medicine market, which has been stimulated by recently discovered obesity drugs. Our discoveries may also find additional relevant indications in the future, which positively affects the size of the market we can address.”

Prof. Katarzyna Koziak, Chief Scientific Officer of BioResearch Pharma S.A., responsible for R&D, said: “We have revealed the high effectiveness of latanoprostic acid in promoting hair growth. This compound, our product BRP-011, initially dismissed in studies of topical treatments, can change the lives of millions of patients suffering from androgenetic alopecia, but also alopecia areata. The results of studies conducted with people diagnosed with androgenetic alopecia were the basis for the patent. Europe is an attractive market in which BRP-011 has the potential for commercial success, as confirmed, among other things, by analyses from CRO IQVIA (data on file), one of the largest global pharmaceutical market monitoring companies.”

BRP-007—A NEW STANDARD OF TREATMENT FOR PATIENTS WITH PSORIASIS

Psoriasis represents the largest market in immunodermatology. Psoriasis manifests as skin lesions on many areas of the body. Patients experience itching and pain, which has a negative impact on their quality of life.

Globally, about 60 million people live with various forms of psoriasis. According to the CRO IQVIA report, by 2028 the value of this market could reach about €29 billion in the US and €40 billion worldwide, achieving a compound annual growth rate (CAGR) of 5%. The disease is a significant social problem, affecting about 2% of the population, with two observed peaks of onset age in the 20–30 and 50–60 brackets. About 94% have mild to moderate disease.

The invention of BioResearch Pharma S.A. (BRP-007) has the potential to become an important topical treatment for mild to moderate psoriasis, due to its unique mechanism of action and safety profile. The product is protected by patents in the United States, Europe and Australia. A report prepared by CRO IQVIA confirms that there are at least 10 million people affected by psoriasis in the countries covered by the patent.

BRP's analyses, which are the basis for the granting of patent protection, confirm that BRP-007's mechanism of action, which is different from existing topical drugs for psoriasis patients, gives it the opportunity to achieve a significant competitive advantage. Topical therapies are the mainstay of psoriasis treatment, accounting for about 80% of all prescriptions written by dermatologists in the US and 85% in the EU (data for Q1 2023, according to the CRO IQVIA analysis).

According to **Prof. Katarzyna Koziak**, “BRP-007 represents an opportunity for a differentiated, safe and well-tolerated new therapy that could become a mainstay of topical treatment in plaque psoriasis, which affects more than 90% of patients with psoriasis.”

Repurposing—1/3 the cost, 1/3 the risk, and 1/3 the time for developing new drugs

The strategy of repurposing dermatological drugs adopted by BioResearch Pharma opens up the opportunity to expedite the development of these treatments, dividing the duration of this process by three (from 12–17 years to about 3–5 years),⁶ at less risk and cost than the traditional process of developing new drugs.

Using substances with a proven safety and efficacy profile, the company is developing new drugs with a novel mechanism of action, addressing unmet medical needs.

About BRP:

BioResearch Pharma S.A. is a pharmaceutical company specializing in novel topical dermatological therapies. Repurposing of known, clinically tested medicinal substances is the foundation of BRP's business model, which is to enable faster commercialization—bringing effective and safe therapies to the market. The company is currently conducting projects to develop innovative drugs for topical treatment of androgenetic alopecia (BRP-011) and psoriasis (BRP-007).

The company was founded in 2021 by Łukasz Zybaczyński, a manager and physician with many years of experience in global pharmaceutical companies such as Eli Lilly, Merck & Co., and Merck KGaA; and Prof. Katarzyna Koziak from the Medical University of Warsaw, a biologist and the inventor of innovations being developed by BRP. The company's largest investor is Marian Popinigis, co-founder and former CEO of the biotech company BLIRT S.A. (sold in 2022 to life sciences group Qiagen). Popinigis is also a co-founder of the exchange-listed MERCOR S.A., and Ambient System Sp. z o.o.

www.bioresearchpharma.com

For additional information please contact:

Beata Cioczek | PR LAB

T: + 48 516 717 584

e-mail: beata.cioczek@prlab.pl

⁶ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292808/>